Start-Up Previews (5/05)
Executive Summary
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, New Approaches to Heart Valve Repair and Replacement, features profiles of 3F Therapeutics, Arbor Surgical Technologies and Heart Leaflet Technologies. Plus these Start-Ups Across Health Care: Neotropix, NeuroHealing Pharmaceuticals, Othera Pharmaceuticals and Vitra Bioscience.
You may also be interested in...
Swiss Finally Beat EMA On New Drug Approval Times
More rolling reviews, a reduction in review rounds, and a rise in applications through two international regulatory collaboration initiatives were among the factors behind a reduction in new drug authorization times in Switzerland last year. However, “submission gaps” versus other regulators remain a problem.
Sanofi Abandons Oral SERD Breast Cancer Drug As Pipeline Woes Mount
The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.
ICH Finalizes Guide To Cutting Down On Rat Carcinogenicity Studies
An ICH guideline describes the “weight of evidence” criteria that in some cases may provide an adequate assessment of human carcinogenicity risk without the need for data from a two-year rat carcinogenicity study.